GSK moves to dismiss Moderna counterclaims in US vaccine patent suit
By Nick Robertson ( January 10, 2025, 16:46 GMT | Insight) -- GlaxoSmithKline responded to Moderna’s counterclaims in a pair of US patent infringement suits over the Covid and RSV vaccines with a motion-to-dismiss for failure to state a claim.Pharma giant GlaxoSmithKline filed a response to Moderna’s answer and counterclaims to a pair of patent infringement suits yesterday, moving to dismiss Moderna’s claim of prosecution laches....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.